What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile

The March 2026 FDA approval of semaglutide 7.2 mg (Wegovy HD; Novo Nordisk) has expanded options for pharmacists and clinicians treating adults with obesity. But it has also prompted questions about whether the higher dose carries meaningfully greater risk than the established 2.4 mg formulation. A close look at the clinical evidence suggests the answer is more nuanced than prevailing concerns may imply.^1,2

A New High-Dose Option for Obesity Management

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a well-established efficacy and safety record. Semaglutide 7.2 mg received FDA approval to reduce excess body weight and maintain long-term weight reduction in adults with obesity or overweight with at least 1 weight-related condition. The approval was granted to patients who have already tolerated the 2.4 mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated.^1,2

The accelerated review—completed in just 54 days under the FDA's Commissioner's National Priority Voucher pilot program—was supported by data from the phase 3b STEP UP trial (NCT05646706), a 72-week, randomized, double-blind, placebo-controlled study enrolling 1407 adults with obesity and a body mass index of at least 30.^2,3

Superior Weight Loss Compared With 2.4 mg

The STEP UP trial achieved its primary endpoint: semaglutide 7.2 mg produced statistically significant and superior weight loss versus placebo at 72 weeks. Based on the trial product estimand—reflecting outcomes if all participants adhered to treatment—the 7.2 mg group achieved a mean weight loss of 20.7%, compared with 17.5% for the 2.4 mg group and 2.4% for placebo. Under the treatment policy estimand, which accounts for real-world nonadherence, the 7.2 mg group achieved 18.7% mean weight loss versus 15.6% for the 2.4 mg group (estimated treatment difference [ETD]: –3.1%; 95% CI, –4.7% to –1.6%; P < .0001) and 3.9% for placebo (ETD: –14.8%; 95% CI, –16.2% to –13.4%; P < .0001).^2-4

Notably, 89% of participants receiving semaglutide 7.2 mg achieved at least 5% body weight loss versus 38% in the placebo group. Nearly one-third (31.2%) achieved 25% or greater weight reduction—a threshold rarely met with currently approved pharmacotherapies. For patients with obesity and type 2 diabetes, the 7.2 mg dose delivered a mean weight loss of 13.2% to 14.1% with hemoglobin A1c reductions comparable to the 2.4 mg dose.^2-4

Adverse Event Profile: Comparable to 2.4 mg

Pharmacists counseling patients about semaglutide 7.2 mg should be familiar with both the similarities and differences in its adverse event profile relative to semaglutide 2.4 mg.

Across both doses, gastrointestinal effects remain the most frequently reported adverse events, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These are consistent with the established GLP-1 receptor agonist class profile, tend to be mild to moderate in severity, and diminish over time as the dose is escalated. Patients should be counseled to take their dose with or without food, stay well-hydrated, eat smaller and more frequent meals, and avoid high-fat foods to minimize gastrointestinal discomfort.^1,2

Importantly, serious adverse events in the STEP UP trial occurred in 6.8% of participants receiving semaglutide 7.2 mg, compared with 10.9% of those receiving semaglutide 2.4 mg and 5.5% of those receiving placebo, indicating that the higher dose did not drive a disproportionate increase in serious adverse events.³

One area of distinction is dysesthesia—an umbrella term for abnormal skin sensations, including burning, tingling, numbness, or altered sensitivity. In STEP UP, dysesthesia occurred more frequently with semaglutide 7.2 mg (22.9%) versus 2.4 mg (6.0%) and placebo (0.5%). The FDA noted that these events generally resolved spontaneously or with dose reduction and is conducting further investigations into this signal. Pharmacists should proactively counsel patients receiving semaglutide 7.2 mg to report any new sensory symptoms and understand that this side effect is typically self-limiting.^2,3

Contextualizing the Risk: What Pharmacists Should Know

Concerns that a higher dose automatically equates to a higher burden of serious adverse events are not supported by the STEP UP data. The serious adverse event rate was numerically lower in the 7.2 mg group than in the 2.4 mg group in the trial. While the dysesthesia finding warrants monitoring and patient counseling, it did not translate into increased rates of treatment discontinuation that would undermine the overall favorable risk-benefit profile established for semaglutide 7.2 mg.³

Semaglutide 7.2 mg also carries a boxed warning for the potential risk of thyroid C-cell tumors, consistent with the entire semaglutide product family. It should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2—the same contraindications that apply to semaglutide 2.4 mg.¹

For patients who have not achieved their therapeutic weight loss goals on semaglutide 2.4 mg, high-dose semaglutide may represent a clinically appropriate next step before consideration of bariatric surgery. Pharmacists are well-positioned to support shared decision-making by reviewing this evidence with patients, setting accurate expectations about gastrointestinal tolerability and dysesthesia, and reinforcing the lifestyle modifications that amplify efficacy across all semaglutide doses.^1,3,4

REFERENCES

1. FDA approves fourth product under National Priority Voucher Program, higher dose semaglutide. News Release. FDA. Released March 19, 2026. Accessed May 11, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

2. Halpern L. FDA approves higher-dose semaglutide under accelerated review program. Pharmacy Times. Published March 19, 2026. Accessed May 11, 2026. http://pharmacytimes.com/view/fda-approves-higher-dose-semaglutide-under-accelerated-review-program

3. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8. Poster presented: American Diabetes Association (ADA) 85th Scientific Sessions, June 20–23, 2025, Chicago, IL. Accessible at: https://sciencehub.novonordisk.com/content/dam/sciencehub/global/en/congresses-and-scientific-publications/congresses/ada2025/Wharton/documents/ADA25_STEP_UP_ePoster_slides.pdf

4. Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence. News Release. Novo Nordisk. Released January 17, 2025. Accessed May 11, 2026. https://www.globenewswire.com/news-release/2025/01/17/3011376/0/en/Novo-Nordisk-A-S-Semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-STEP-UP-obesity-trial-and-18-7-regardless-of-treatment-adherence.html